Loading...
•
Dec 31, 2022
4DMT Q4 2022 Earnings Report
Reported full year 2022 financial results and provided operational highlights.
Key Takeaways
4DMT reported full year 2022 financial results, highlighting the validation of their Therapeutic Vector Evolution platform and progress in their clinical pipeline. The company's cash position is expected to fund operations into the first half of 2025.
Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for cystic fibrosis lung disease, and 4D-310 for Fabry disease cardiomyopathy
Demonstrated robust clinical gene delivery, tolerability and initial biological activity with first three customized and evolved vectors generated from Therapeutic Vector Evolution platform
Expanded preclinical pipeline with large market geographic atrophy (GA) and alpha-1 antitrypsin deficiency lung disease (AATLD) programs
Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025
4DMT
4DMT
4DMT Revenue by Segment
Revenue by Segment
Collaboration & license rev. Revenue
CapyFin.com Forward Guidance
4DMT is on track for multiple clinical data updates on lead clinical-stage product candidates during 2023.
Positive Outlook
- Complete enrollment of the Phase 2 randomized Dose Expansion stage of the PRISM clinical trial in Q4
- Initiate enrollment of the Phase 2 SPECTRA clinical trial for DME in Q3
- Present interim data from the Dose Exploration stage (Cohorts 1 and 2) of the Phase 1/2 clinical trial at a scientific conference in Q2
- Update on development plan for modulator combination in 2H
- FDA feedback on response letter expected in Q2